Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.

Targeted oncology - 1 May 2022

Frampton James E

Abstract excerpt

Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of adults with completely resected, stage IB-IIIA, EGFR sensitizing mutation (exon 19 deletion or exon 21 [L858R] substitution)-positive non-small cell lung cancer (NSCLC). In the pivotal ADAURA trial in adults with completely resected,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Quality of Life

Source

Identifiers

PMID: 35713772
DOI: 10.1007/s11523-022-00883-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.PMID 35713772Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.Semantic proximity Read ↗

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Semantic proximity Read ↗

Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.Semantic proximity Read ↗

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.Semantic proximity Read ↗

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.Semantic proximity Read ↗

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.